Gastroenterology Industry Analysis, Competitive Intelligence and Strategic Business Report 2025 with Insights on 41 Market Players
Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Gastroenterology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Gastroenterology was valued at US$34.1 Billion in 2024 and is projected to reach US$45.7 Billion by 2030, growing at a CAGR of 5.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Gastroenterology market.
The growth of the gastroenterology market is driven by several factors that combine advancements in technology, increasing disease prevalence, and a focus on patient-centered care. A key driver is the rising global prevalence of gastrointestinal diseases, particularly conditions like IBD, colorectal cancer, and NAFLD, which are more common due to modern lifestyle factors such as poor diets, smoking, and sedentary lifestyles. As these diseases become more prevalent, there is a greater demand for gastroenterology specialists, diagnostics, and treatments to manage these conditions.
Additionally, technological innovations in diagnostics and treatments, such as AI-assisted endoscopy and minimally invasive surgeries, are improving the accuracy, speed, and patient outcomes associated with gastroenterology procedures. The integration of genomics into gastroenterology is also driving growth, as the field moves toward personalized medicine and targeted therapies for gastrointestinal diseases. The increasing focus on preventive care is another significant growth driver. With improved access to screenings for colorectal cancer, hepatitis, and other gastrointestinal diseases, healthcare systems can catch these conditions at earlier stages, leading to more effective treatment and improved survival rates.
Moreover, the expanding middle class in emerging markets is contributing to the global growth of gastroenterology services, as more people seek specialized care for digestive disorders. Public health campaigns, government initiatives, and international efforts to raise awareness of gastrointestinal diseases are further fueling the demand for gastroenterology services.
Finally, the growing interest in gut microbiota and its role in gastrointestinal health and overall well-being is sparking new research and treatment options, positioning gastroenterology at the forefront of medical innovation. Together, these factors are driving the expansion of the gastroenterology market and enhancing the quality of care for patients with digestive diseases worldwide.Report ScopeThe report analyzes the Gastroenterology market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Drug Type (Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, Other Drug Types); Disease Type (Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
Market Growth: Understand the significant growth trajectory of the Biologics / Biosimilars segment, which is expected to reach US$11.3 Billion by 2030 with a CAGR of a 3.8%. The Antacids segment is also set to grow at 4.8% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $9.3 Billion in 2024, and China, forecasted to grow at an impressive 7.7% CAGR to reach $8.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Questions Answered:
How is the Global Gastroenterology Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as AbbVie Inc., Abbott Laboratories, AstraZeneca plc, Bayer AG, Bausch Health Companies Inc. and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 41 companies featured in this Gastroenterology market report include:
AbbVie Inc.
Abbott Laboratories
AstraZeneca plc
Bayer AG
Bausch Health Companies Inc.
Boehringer Ingelheim GmbH
Boston Scientific Corporation
Cipla Ltd.
Ferring Pharmaceuticals
GI Alliance
GlaxoSmithKline plc
Johnson & Johnson
Medtronic plc
Novartis AG
Olympus Corporation
Pfizer Inc.
Salix Pharmaceuticals
Sanofi S.A.
Sebela Pharmaceuticals
Takeda Pharmaceutical Company
Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.What's Included in This Edition:
Tariff-adjusted market forecasts by region and segment
Analysis of cost and supply chain implications by sourcing and trade exposure
Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
Finalized tariff impacts and new trade agreement effects
Updated projections reflecting global sourcing and cost shifts
Expanded country-specific coverage across the industry
Key Attributes
Report Attribute
Details
No. of Pages
401
Forecast Period
2024-2030
Estimated Market Value (USD) in 2024
$34.1 Billion
Forecasted Market Value (USD) by 2030
$45.7 Billion
Compound Annual Growth Rate
5%
Regions Covered
Global
MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of COVID-19 and a Looming Global Recession
Gastroenterology - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
MARKET TRENDS & DRIVERS
Increasing Prevalence of Gastrointestinal Disorders Drives Demand for Gastroenterology Services and Treatments
Here's the Story: How Advancements in Endoscopic Technology Are Revolutionizing Gastroenterology Diagnostics
Rising Awareness of Digestive Health and Wellness Fuels Growth in Preventive and Diagnostic Gastroenterology Services
Technological Innovations in Minimally Invasive Procedures Expand Treatment Options for Gastrointestinal Disorders
Surge in Aging Populations Globally Increases the Need for Gastroenterology Care and Disease Management
Here's How the Growing Focus on Personalized Medicine is Shaping the Future of Gastroenterology Treatments
Rising Incidence of Inflammatory Bowel Diseases (IBD) and Celiac Disease Strengthens the Business Case for Specialized Care
Expanding Role of Telemedicine and Remote Monitoring Drives Access to Gastroenterology Services in Underserved Areas
Increasing Research and Clinical Trials in Microbiome and Gut Health Create New Opportunities for Therapeutic Advancements
Here's How Advances in Artificial Intelligence and Machine Learning are Revolutionizing Gastroenterology Diagnostics
Growing Demand for Targeted Therapies and Biologics in Treating Gastrointestinal Disorders Expands Treatment Options
Global Increase in Obesity and Lifestyle-Related Disorders Drives Growth in Gastroenterology-Based Disease Prevention
For more information about this report visit https://www.researchandmarkets.com/r/fxze64
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Chatbot platform Character.AI unveils video generation, social feeds
A platform for chatting and role-playing with AI-generated characters, announced in a blog post on Monday that it is rolling out a slate of multimedia features. These features include AvatarFX, video-generation model, plus Scenes and Streams, which allow users to create videos featuring their characters and then share them on a new social feed. " started as 1:1 text chat and today we're evolving to do so much more, inspired by what our users have told [us] they want to see on the platform," the company wrote in the blog post. began rolling out AvatarFX to subscribers last month, but now all users can create up to five videos each day. When creating a video with AvatarFX, users can upload a photo to serve as the basis for the video clip, choose a voice, and write out dialogue for the character. There's an option to upload an audio clip to inform the sound of the voice, though this feature was not working well enough to test upon rollout. Users can turn these videos into Scenes, where their characters can slip into pre-populated storylines that other users create. Scenes are currently available on the mobile app, but Streams, which allows users to create "dynamic moments between any two Characters," is coming this week on both web and mobile. These Scenes and Streams can be shared to a new community feed, which is coming soon in the mobile app. has a track record of abuse on its platform; parents have filed lawsuits against the company, claiming chatbots attempted to convince their children to self-harm, to kill themselves, or to kill their parents. One 14-year-old boy died by suicide after he was encouraged to do so by a bot, with whom he had developed an unhealthy, obsessive relationship. As expands its multimedia offerings, it also expands the potential for these products to be abused. As told TechCrunch when it announced AvatarFX, the platform blocks users from uploading photographs of real people -- whether they're celebrities or not -- and obscures their likeness into something less recognizable. For example, here's uncanny valley version of Mark Zuckerberg: But when it comes to artwork depicting celebrities, does not flag the images as representing real people -- however, these sorts of depictions would be less likely to deceive someone into believing that a deepfake is real. Plus, watermarks each video, though it is possible for bad actors to navigate around that safeguard. Here is an example of an attempted deepfake based on an illustration of Elon Musk: testing the anti-deepfake guardrails on character ai's avatarfx Even if this video had been generated with Elon Musk's actual voice, it would still be relatively clear that this is an animated version of an illustration -- but the possibility for abuse remains evident. "Our goal is to provide an engaging space that fosters creativity while maintaining a safe environment for all," said in its blog post. This article originally appeared on TechCrunch at
Yahoo
32 minutes ago
- Yahoo
PAIG AI Rebrands as Trust3 AI to Lead the Way in Trusted AI Adoption
SAN FRANCISCO, June 2, 2025 /PRNewswire/ -- PAIG AI, a leading provider of AI governance and performance solutions, has officially rebranded as Trust3 AI. This strategic rebranding reflects the company's commitment to help enterprises address the growing complexities surrounding AI reliability, governance, and security. Organizations adopting AI today face significant challenges—from ensuring the reliability of AI outputs to managing regulatory compliance and mitigating security risks. Without comprehensive visibility into AI and agent activities across their enterprise, organizations struggle to build the trust necessary for widespread adoption. Trust3 AI aims to simplify that process by equipping businesses with a unified trust layer that ensures confidence at every stage of the AI application lifecycle. The rebranding reinforces our mission to help enterprises seamlessly integrate governance, transparency, and accountability into their AI systems, empowering them to move from experimentation to operationalization without compromise. A Platform Built to Enable Trust Trust3 AI's innovative platform focuses on three core pillars of trust-building across AI systems, Reliability, Governance, and Security: Reliability – Trust3 AI enhances the consistency and accuracy of AI systems by providing domain-enriched semantic layers and AI-driven analytics. It ensures AI systems deliver accurate, efficient, and consistent results to prevent errors, hallucinations, and inconsistent outputs that undermine trust and disrupt business processes. Trust3 AI enables enterprises to deliver dependable outcomes across AI Story: A healthcare client leveraging Trust3 AI achieved a 40% improvement in the accuracy of its clinical AI tools, significantly enhancing patient care outcomes. Governance: With advanced governance tools, Trust3 AI helps enterprises streamline compliance and maintain oversight. Features include continuous audit trails, AI inventories for tracking deployed solutions, and compliance with global frameworks like GDPR and the EU AI Insight: With stricter AI regulations becoming the standard, Trust3 AI simplifies governance, enabling enterprises to focus on scaling innovation while staying compliant. Security: Trust3 AI addresses security concerns by creating robust guardrails to mitigate risks such as malicious use cases and data exposure. Businesses can confidently scale their AI initiatives with proactive risk mapping and adaptive security Stats: 97% of organizations using generative AI report security concerns. Trust3 AI eliminates these risks, fostering safe innovation. Why Trust Matters in AI The name Trust3 AI underscores the company's belief that trust is a continuous process spanning the full App lifecycle with AI . Unlike one-off solutions, the platform integrates reliability, governance, and security into every stage, allowing businesses to deploy AI systems that are as trustworthy as they are innovative. "Trust isn't just a checkbox; it's a competitive advantage. With Trust3 AI, we're not just providing technology, but fostering partnerships to ensure that AI adoption is informed, transparent, and ethical," Neeraj Sabharwal, Co-Founder Trust3 AI, added. Advancing AI with Strategic Partnerships Trust3 AI has also strengthened its capabilities through partnerships with industry-leading platforms like Snowflake and Databricks via their startup accelerator programs. These collaborations enhance the seamless integration of Trust3 AI's solutions, supporting customers across industries as they adopt next-generation AI platforms. Looking Ahead For enterprises ready to overcome the mounting challenges of AI adoption, Trust3 AI represents a transformation—not just a tool. By focusing on the 3 pillars of reliability, governance, and security, Trust3 AI enables the enterprise-ready future of artificial intelligence. About Trust3 AI Based in San Francisco, Trust3 AI (formerly PAIG AI) is a leader in AI governance, security, and lifecycle management solutions. Trust3 AI's unified platform empowers businesses to adopt AI responsibly by building trust into every AI interaction. Trust3 AI is trusted by organizations across industries, from healthcare to finance, and is proud to be part of the Snowflake and Databricks startup accelerator programs. For more information, visit and follow us on Linkedin Media ContactNeeraj Sabharwalmedia@ View original content: SOURCE Trust3 AI Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
US FDA launches AI tool to reduce time taken for scientific reviews
(Reuters) -The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool, Elsa, aimed at improving efficiency across its operations, including scientific reviews. "Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers," said FDA Commissioner Marty Makary. The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets. Once the FDA receives an application for a potential drug approval, it has six to 10 months to make a decision. Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts. "Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff," the FDA said. In May, the regulator said it would fully integrate AI by June 30, following an experimental run.
